Company Profile

PolarityTE Inc (AKA: RegenETP Inc~PolarityTE MD Inc)
Profile last edited on: 12/2/2023      CAGE: 8DM08      UEI: LMTQKMVNFVN7

Business Identifier: Translational regenerative medicine company
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1960 South 4250 West
Salt Lake City, UT 84104
   (800) 560-3983
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

PolarityTE is a publicly traded (NASDAQ:PTE) commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovery, design and development of a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $244,894
Project Title: Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds

Key People / Management

  David B Seaburg -- Chief Executive Officer

  Kolby Day -- Senior Vice President Operations, Corporate General Manager

  Rich Haerle -- VP of Investor Relations & Strategy

  Richard Hague -- Chief Operating Officer

  Cameron J Hoyler -- Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy

  Jacob Alexander Patterson -- Interim Chief Financial Officer

  Jacqueline Reed -- TitleDirector of Grants and Contracts

  Nikolai Anton Sopko -- Chief Scientific Officer and VP of R&D